Stiefel Laboratories Implements Medidata Rave to Achieve Immediate Cost Savings across Global Clinical Studies
FOR IMMEDIATE RELEASE
Stiefel Laboratories Implements Medidata Rave® to Achieve
Immediate Cost Savings across Global Clinical Studies
Medidata Solutions Selected for Commitment to Customer Needs,
Broad Functionality and Integration Capabilities
NEW YORK, N.Y. – January 20, 2009 – Medidata Solutions, a leading provider of clinical trial solutions, today announced that Stiefel Laboratories has selected Medidata Rave® as the central component of its clinical data management process. Medidata Rave has already helped Stiefel to significantly reduce upfront study costs and expanded use of this electronic data capture (EDC), management and reporting solution is expected to play a key role in helping Stiefel to achieve a projected 35 percent reduction in data management costs during the next three years.
Stiefel, a global pharmaceutical company headquartered in the United States, develops skin care products used by millions of people each year in more than 100 countries. Prior to implementing Medidata Rave, Stiefel conducted its clinical trials using paper-based systems. In order to streamline work processes across trial teams worldwide, the company decided to implement an electronic system for data capture. Stiefel’s team opened its search for an EDC system with broad functionality that could serve as the end repository for all clinical data and easily export data directly into its SAS environment. After a formal evaluation of nine EDC vendors in March 2008, Medidata Rave stood out to Stiefel among competing solutions as the system that worked best in a straight-to-SAS environment and could also be hosted off-site while supporting a knowledge transfer of the database build functionality.
“We chose Medidata Rave based on a range of criteria, including ease-of-use for sites and monitors, simple and fast study start-up, zero-footprint and browser-independent capabilities, no requirement for a back-end CDMS, availability of real-time, on-demand tools and Medidata’s dedication to customer support,” said Gavin Corcoran, M.D., chief scientific officer at Stiefel. “As we evaluated systems, we were also impressed with Medidata’s continued expansion of Rave’s features and functionality. We expect that Medidata will continue to invest heavily in further innovation and product development, which will only help us down the road.” With help from Medidata’s Professional Services staff and a contract research organization (CRO), Stiefel launched its first trial using Rave in less than 10 weeks. By leveraging Medidata’s flexible and interactive implementation process, Stiefel was able to reduce study start up time
from an average of 10 weeks to an average of six weeks. With three Rave studies already in place in the US, Canada, Germany, Iceland and Belize, Stiefel has achieved a reduction in data management costs and expects those savings to increase as it starts to build out global libraries. Stiefel plans to have six Rave studies up and running by March 2009, with a long-term goal of deploying 35 trials during the next three years. The company is using Medidata Rave’s eLearning modules to ensure consistent training across globally diverse sites and studies, and also intends to explore leveraging Rave to enable a seamless integration between its clinical trial management system (CTMS) and integrated web response system (IWRS) in an effort to maximize the value of its current and future technology investments.
“By tightly linking these systems, we can start to establish a data ‘pipeline,’ where data is entered once and then pulled to all other systems, further improving efficiencies and making relevant data available to the entire clinical team as quickly as possible,” added Corcoran. “We are very pleased that Medidata will play a key role in supporting Stiefel’s continued commitment to advancing dermatology and the development of skin care treatments around the world,” said Tarek Sherif, CEO, Medidata Solutions. “Stiefel’s selection of Medidata Rave speaks not only to our ongoing dedication to product innovation and customer support, but also to our mission of helping sponsors attain operational excellence in clinical research.”
About Medidata Solutions Worldwide
Medidata Solutions (www.mdsol.com) is a leading provider of clinical trial solutions that enable the world’s most advanced life science organizations to maximize the value of their clinical research investments by putting powerful tools into researchers’ hands. A pioneer since 1999 in innovative technologies for planning and managing clinical studies – including protocol design; clinical data capture, management and reporting; and trial contracting and negotiation – Medidata Solutions and its global network of business partners address the unique needs of sponsors and sites of all sizes. With deep expertise in conducting studies across all phases and therapeutic areas, on six continents and in more than 80 countries, Medidata Solutions helps clinical researchers reduce trial cycle times, achieve early visibility to reliable clinical data, and maintain strict fiscal responsibility, while safely accelerating the process of bringing lifeenhancing treatments to market.
About Stiefel Laboratories, Inc.
Stiefel Laboratories is enthusiastically committed to advancing dermatology and skin science around the world. The company's deeply-rooted dedication and drive for innovation along with its sole focus on dermatology has led Stiefel to become the largest independent dermatology company in the world. In addition to more than 30 wholly-owned subsidiaries, six manufacturing plants and a global research and development network, Stiefel's most valuable asset is its global network of nearly 4,000 driven associates.
By combining expertise, knowledge and imagination, Stiefel delivers exceptional ethical, overthe-counter and aesthetic products to its customers in more than 100 countries around the world, ultimately providing a unique Stiefel skin health experience. Stiefel also is committed to improving today's treatments and exploring tomorrow's innovations. Each year, the company invests more than $100 million USD in developing the most advanced skin health solutions. Additionally, Stiefel supplements its research and development efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel, visit www.stiefel.com.
Contact:
Susan McCarron
Lois Paul & Partners
781.782.5767
Susan_McCarron@lpp.com